While NSE and S100B are increased in the setting of hemolysis42,43 - frequently occurring during ECMO treatment - these novel markers might overcome this limitation, but remain yet to be evaluated in ECMO patients not suffering from cardiac arrest. The gene discussed is ENO2; the disease is cardiac arrest.